Live Breaking News & Updates on Zhuang Shilihe|Page 18

Stay updated with breaking news from Zhuang shilihe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

China-produced Vaccines Await Approval by EU and WHO-Dahe.cn - The first brand of local news website in Henan.


Source:
2021-05-06 17:23
The European Medicines Agency (EMA) has started a rolling review of China s Sinovac COVID-19 vaccine, the EU s top drug regulator announced Tuesday, and experts said that once the vaccine is approved, China will further fulfill its international responsibilities as a major power and provide support to the international community in the pandemic fight.
Sinovac and another China-produced COVID-19 jab, Sinopharm, are also under WHO assessment for emergency use, and results are anticipated in a week.
The EMA said the decision on whether Sinovac can be marketed in Europe will be based on preliminary results from laboratory and clinical studies. ....

Tao Lina , Zhuang Shilihe , Wang Yi , Chinese Embassy , European Medicines Agency , Global Times , Good Manufacturing Practice , Chinese State Councilor , South Asia , South Asian , தாவோ லினா , வாங் இ , சீன தூதரகம் , உலகளாவிய முறை , நல்ல உற்பத்தி ப்ர்யாக்டீஸ் , சீன நிலை கவுன்சிலர் , தெற்கு ஆசியா , தெற்கு ஆசிய ,

China: U.S. Prioritizing Vaccines for Americans Hurts Its 'Shaky Leadership'


China: U.S. Prioritizing Vaccines for Americans Hurts Its ‘Shaky Leadership’
China’s state-run
Global Times on Wednesday continued its effort to capitalize on the coronavirus pandemic in India by accusing the United States of selfishness for “sitting on tens of millions of vaccines” instead of sharing them with other nations.
“Stockpiling the COVID-19 [Chinese coronavirus] vaccines may help accelerate the U.S. vaccination pace for now, but such selfish deed also undermines the country’s shaky leadership and credibility in international society,” the
Global Times lectured, presumably hoping its readers will not remember China’s mad dash to buy up all of the medical protective equipment in the world before the Wuhan coronavirus became a pandemic. ....

United States , Zhuang Shilihe , Joe Biden , Chinese Communist Party , Global Timeson Wednesday , Global Times , President Joe Biden , Donald Trump , ஒன்றுபட்டது மாநிலங்களில் , ஓஹோ பிடென் , சீன கம்யூனிஸ்ட் கட்சி , உலகளாவிய முறை , ப்ரெஸிடெஂட் ஓஹோ பிடென் , டொனால்ட் துருப்பு , தடுப்பு மருந்துகள் ,

Mixing COVID-19 vaccine shots 'acceptable' though efficacy remains under study


Mixing COVID-19 vaccine shots ‘acceptable’ though efficacy remains under study
Hu Yuwei Published: Apr 29, 2021 11:21 PM
A medical worker inoculates a recipient with the second dose of COVID-19 vaccine at a temporary vaccination site in Haidian District of Beijing, capital of China. Photo: Xinhua
Recipients can accept a second COVID-19 shot developed using the same technique but by a different producer under special conditions, a Chinese health official said on Thursday, vowing to increase supply to ensure success of the injection of the second shot amid reports of vaccine shortage in some places.   
In response to the difficulty in receiving the second shots reported by some people, Wang Bin, an official from China s National Health Commission (NHC), said at a press conference on Thursday that supply will be enhanced to meet demand and priority would be given to people waiting for their second shot. ....

Wang Bin , Hong Kong , United Kingdom , Anhui Zhifei Longcom , Gao Fu , Zhuang Shilihe , Xinhua Ren Chao , China National Health Commission , Sinovac Biotech , Chinese Center , Haidian District , Ren Chao , National Health Commission , Anhui Zhifei Longcom Biologic , Global Times , Disease Control , வாங் பின் , ஹாங் காங் , ஒன்றுபட்டது கிஂக்டம் , கொ ஃபூ , சீனா தேசிய ஆரோக்கியம் தரகு , சீன மையம் , ரென் குழப்பம் , தேசிய ஆரோக்கியம் தரகு , உலகளாவிய முறை , நோய் கட்டுப்பாடு ,

Sinovac vaccine effective against virus variants in Brazil; efficacy rises if injection interval is more than 21 days


Sinovac vaccine effective against virus variants in Brazil; efficacy rises if injection interval is more than 21 days
Hu Yuwei Published: Apr 12, 2021 10:43 PM
Guarani indigenous chief Jurema Nunes, receives a CoronaVac vaccination shot during a COVID-19 vaccination campaign in Marica, Brazil, on January 20. Photo: VCG
China s Sinovac COVID-19 vaccine has 50.7 percent efficacy and has proved to be effective against the variants known as P1 and P2 that are prevalent in Brazil, latest data showed. Moreover, the Sinovac vaccine s efficacy rate can climb to 62.3 percent with an interval of more than 21 days between doses rather than 14 days.
The findings appear in the latest report released on Sunday by Sao Paulo s state-owned Butantan Institute, which tested and produced Sinovac s COVID-19 inactivated vaccine named CoronaVac.  ....

Sao Paulo , Estado Do Rio , Zhuang Shilihe , Jurema Nunes , Liu Peicheng , University Of Chile , Chile Ministry Of Health , Butantan Institute , Global Times , 50 7 , ஸ்ம் பாலொ , எஸ்டாடோ செய் ரியோ , பல்கலைக்கழகம் ஆஃப் சிலி , சிலி அமைச்சகம் ஆஃப் ஆரோக்கியம் , புத்தாண்தான் நிறுவனம் , உலகளாவிய முறை ,